MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
MannKind is advancing a dry powder inhalation formulation of ralinepag for partner United Therapeutics, which recently reported positive Phase 3 data for the oral version of the drug. United Therapeutics made a $5 million payment to support the program, with MannKind eligible to receive up to $35 million in development milestones and 10% royalties on net sales.
Key figures
- Drug Name
- Ralinepag DPI (MNKD-1501)
- Phase Of Trial
- Phase 1
- Payment received usd
- 5000000
- Royalty rate percent
- 10
- Tyvaso dpi 2025 revenue
- $1.3B
- Potential milestones usd
- 35000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.